3.64
-0.06 (-1.62%)
| Penutupan Terdahulu | 3.70 |
| Buka | 3.70 |
| Jumlah Dagangan | 2,290,589 |
| Purata Dagangan (3B) | 4,444,883 |
| Modal Pasaran | 1,327,675,392 |
| Harga / Jualan (P/S) | 201.66 |
| Harga / Buku (P/B) | 5.98 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 13 May 2026 |
| Margin Operasi (TTM) | -1,239.23% |
| EPS Cair (TTM) | -0.910 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -54.00% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 19.02% |
| Nisbah Semasa (MRQ) | 4.07 |
| Aliran Tunai Operasi (OCF TTM) | -77.70 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -47.04 M |
| Pulangan Atas Aset (ROA TTM) | -26.04% |
| Pulangan Atas Ekuiti (ROE TTM) | -79.43% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | AtaiBeckley Inc. | Bercampur | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 5.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | 3.0 |
| Purata | 1.50 |
|
ATAI Life Sciences NV is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. Its product candidates include COMP360/Psilocybin therapy, PCN-101/R-ketamine, RL-007/Compound, DMX-1002/Ibogaine, GRX-917/Deuterated etifoxine, VLS-01/DMT, EMP-01/MDMA derivative, RLS-01/Salvinorin A, KUR-101/Deuterated Mitragynine, and DMX-1001/Noribogaine. The business operates geographically in two regions being the United States and Germany. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 7.78% |
| % Dimiliki oleh Institusi | 31.48% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Foresite Capital Management Vi Llc | 31 Dec 2025 | 2,750,000 |
| Ally Bridge Group (Ny) Llc | 31 Dec 2025 | 1,713,105 |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 25.00 (HC Wainwright & Co., 586.81%) | Beli |
| Median | 14.00 (284.62%) | |
| Rendah | 11.00 (Guggenheim, 202.20%) | Beli |
| Purata | 16.67 (357.97%) | |
| Jumlah | 3 Beli | |
| Harga Purata @ Panggilan | 3.81 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Needham | 09 Mar 2026 | 14.00 (284.62%) | Beli | 3.89 |
| HC Wainwright & Co. | 02 Mar 2026 | 25.00 (586.81%) | Beli | 3.68 |
| Guggenheim | 20 Jan 2026 | 11.00 (202.20%) | Beli | 3.85 |
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 16 Jan 2026 | Pengumuman | AtaiBeckley Participates in the 64th Annual ACNP Meeting with Two Scientific Poster Presentations and Hot Topic Presentation |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |